Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | What does FDA approval of orexin receptor agonists mean for Europe?

Jari Gool, MD, Amsterdam UMC, Amsterdam, Netherlands, discusses the approval of orexin receptor agonists for narcolepsy in the US, Japan and China, and what this means for Europe. He describes this as an exciting time for nacrolepsy, with trial participants at European Narcolepsy Network centers reporting substantial improvements in their symptoms. This interview took place at Sleep Europe 2026, which was held in Maastricht, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.